Literature DB >> 10551996

Influence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model. Comparative study with cyclosporine.

K Mizuta1, E Kobayashi, H Uchida, A Fujimura, H Kawarasaki, K Hashizume.   

Abstract

Cholestatic effects have been reported for cyclosporine (CsA), but information is still limited for tacrolimus (TCR). The purpose of this study was to investigate the influence of TCR on biliary bile acid and lipid composition as compared with CsA, using a continuously bile-drained rat model. Adult male Wistar rats received TCR (0.4 mg/kg, 1 mg/kg, and 4 mg/kg) or CsA (2.5 mg/kg, 10 mg/kg, and 25 mg/kg) by intramuscular injection (i.m.) daily for 10 days. On day 7, the common bile duct of all rats was cannulated, then bile was continuously collected for the following 3 days. Bile flow, bile acid secretion rate (BASR), and biliary lipids secretion were measured for each of the groups. TCR increased bile acid-dependent flow (BADF) but with no statistical significance. However, this agent did not influence total bile flow and biliary lipids secretion, while bile acid-independent flow (BAIF) was significantly reduced and bile acid synthesis (mainly cholic acid, CA, synthesis) was increased. In contrast, CsA was cholestatic, showing a tendency to reduce both BADF and BAIF. BASR was dose-dependently suppressed, especially in chenodeoxycholic acid (CDCA). Furthermore, biliary lipids secretions were also significantly decreased under a higher dose of CsA. TCR increased BADF with no influence on total bile flow, having a stimulating effect on CA production, although CsA dose-dependently diminishes CDCA production and consequently reduced bile secretion. Our results suggest that TCR is a less effective agent on cholestasis as compared to CsA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551996     DOI: 10.1007/s001470050234

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  8 in total

1.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

2.  Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat.

Authors:  M Deters; K Nolte; G Kirchner; K Resch; V Kaever
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 3.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

4.  Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model.

Authors:  Michael Deters; Til Klabunde; Gabriele Kirchner; Klaus Resch; Volkhard Kaever
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

5.  Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells.

Authors:  Ahmad Sharanek; Pamela Bachour-El Azzi; Houssein Al-Attrache; Camille C Savary; Lydie Humbert; Dominique Rainteau; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

6.  Biliary diseases in heart transplanted patients: a comparison between cyclosporine A versus tacrolimus-based immunosuppression.

Authors:  J Stief; H U Stempfle; M Götzberger; P Uberfuhr; M Köpple; P Lehnert; C Kaiser; Uwe Schiemann
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

7.  Immunosuppressants and new onset gallstone disease in patients having undergone renal transplantation.

Authors:  Fu-Chao Liu; Pei-Chi Ting; Jr-Rung Lin; Huang-Ping Yu
Journal:  Ther Clin Risk Manag       Date:  2017-10-13       Impact factor: 2.423

8.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.